First Turn Management LLC Purchases New Position in Harrow, Inc. (NASDAQ:HROW)

First Turn Management LLC bought a new stake in Harrow, Inc. (NASDAQ:HROW - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 326,582 shares of the company's stock, valued at approximately $14,683,000. Harrow accounts for approximately 2.3% of First Turn Management LLC's portfolio, making the stock its 22nd biggest position. First Turn Management LLC owned approximately 0.92% of Harrow at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of HROW. Opaleye Management Inc. increased its stake in shares of Harrow by 2.6% in the 1st quarter. Opaleye Management Inc. now owns 3,920,600 shares of the company's stock worth $51,870,000 after purchasing an additional 100,600 shares in the last quarter. Private Capital Management LLC lifted its position in shares of Harrow by 7.8% during the 1st quarter. Private Capital Management LLC now owns 3,012,393 shares of the company's stock valued at $39,854,000 after buying an additional 217,896 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Harrow by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company's stock valued at $24,208,000 after buying an additional 21,253 shares in the last quarter. Rice Hall James & Associates LLC grew its stake in shares of Harrow by 23.1% during the 3rd quarter. Rice Hall James & Associates LLC now owns 314,881 shares of the company's stock valued at $14,157,000 after acquiring an additional 59,019 shares during the period. Finally, Assenagon Asset Management S.A. bought a new stake in Harrow during the 3rd quarter worth approximately $8,572,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HROW has been the subject of a number of recent analyst reports. Craig Hallum upped their price target on shares of Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research report on Friday, October 4th. Lake Street Capital increased their price target on Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Friday, October 4th. Finally, B. Riley restated a "buy" rating and issued a $50.00 price objective on shares of Harrow in a research report on Thursday, August 29th.

Harrow Price Performance

Shares of HROW stock traded up $1.73 during mid-day trading on Tuesday, hitting $39.70. The company had a trading volume of 488,802 shares, compared to its average volume of 514,353. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The stock's 50 day moving average price is $47.89 and its 200-day moving average price is $32.78. Harrow, Inc. has a 52-week low of $8.72 and a 52-week high of $59.23. The company has a market capitalization of $1.41 billion, a P/E ratio of -42.23 and a beta of 0.76.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.